Human association studies have confirmed the importance of insulin and IGF-1 in modulating the Wnt-related molecules and inhibitors; thus, targeting these two signalling pathways as therapeutic interventions in human trials recruiting patients with osteoporosis and/or fractures may be the next step of research. Here, IGF1 is linked to osteoporosis.